advertisement
Qu B 12
Showing records 1 to 12 | Display all abstracts from Qu B106485 Exploring the Association Between Resilience and Quality of Life Among Glaucoma Patients: Sleep Disturbance as a Mediating Factor
Peng Q
Frontiers in medicine 2022; 9: 842864
106854 Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
Chen XL; Fu YJ
International Journal of Ophthalmology 2023; 16: 108-114
106485 Exploring the Association Between Resilience and Quality of Life Among Glaucoma Patients: Sleep Disturbance as a Mediating Factor
Qu B
Frontiers in medicine 2022; 9: 842864
106854 Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
Qu B
International Journal of Ophthalmology 2023; 16: 108-114
106485 Exploring the Association Between Resilience and Quality of Life Among Glaucoma Patients: Sleep Disturbance as a Mediating Factor
Sznajder KK; Chen Q
Frontiers in medicine 2022; 9: 842864
106854 Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
Wang YW; Tang X
International Journal of Ophthalmology 2023; 16: 108-114
106485 Exploring the Association Between Resilience and Quality of Life Among Glaucoma Patients: Sleep Disturbance as a Mediating Factor
Fu J
Frontiers in medicine 2022; 9: 842864
106854 Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
Wang YH
International Journal of Ophthalmology 2023; 16: 108-114
106485 Exploring the Association Between Resilience and Quality of Life Among Glaucoma Patients: Sleep Disturbance as a Mediating Factor
He S
Frontiers in medicine 2022; 9: 842864
106854 Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
Zhou GY
International Journal of Ophthalmology 2023; 16: 108-114
106485 Exploring the Association Between Resilience and Quality of Life Among Glaucoma Patients: Sleep Disturbance as a Mediating Factor
Yang X
Frontiers in medicine 2022; 9: 842864
106854 Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study
Lin MK; Shen JY; Yao J; Li SY; Wu MQ; Peng HZ; Lai MY; Wu RY; Zhang YN; Li Y; Wu XJ; Zhang MC; Guo SP; Sun XH
International Journal of Ophthalmology 2023; 16: 108-114
